

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/974,719	10/09/2001	Dusan Ninkov	12996.5USU1	7844
23552	7590 07/06/2004		EXAMINER	
MERCHANT & GOULD PC P.O. BOX 2903			JAGOE, D	ONNA A
	IS, MN 55402-0903		ART UNIT	PAPER NUMBER
	•		1614	

DATE MAILED: 07/06/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	<del></del>	<del>,</del>			
	Application No.	Applicant(s)			
Advisory Action	09/974,719	NINKOV, DUSAN			
7. <b></b>	Examiner	Art Unit			
	Donna Jagoe	1614			
The MAILING DATE of this communication app	ears on the cover sheet with the	correspondence address			
THE REPLY FILED 26 April 2004 FAILS TO PLACE THE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (*condition for allowance; (2) a timely filed Notice of Appel Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this application in the same in the same of this application is the same in the sa	ation. A proper reply to a high places the application in			
PERIOD FOR R	EPLY [check either a) or b)]				
a) The period for reply expiresmonths from the maili b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WA 706.07(f).	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin S FILED WITHIN TWO MONTHS OF T	ng date of the final rejection. HE FINAL REJECTION. See MPEP			
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Off timely filed, may reduce any earned patent term adjustment. See 37	of extension and the corresponding amount of the shortened statutory period for reply fice later than three months after the ma	ount of the fee. The appropriate extension originally set in the final Office action; or			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered because:					
(a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) ☐ they raise the issue of new matter (see Note below);					
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following rejection(s):					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	d be allowable if submitted in a se	eparate, timely filed amendment			
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request fo application in condition for allowance because:	r reconsideration has been cons	idered but does NOT place the			
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.					
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed:					
Claim(s) objected to:					
Claim(s) rejected: <u>1 and 4-20</u> .					
Claim(s) withdrawn from consideration:					
8. The drawing correction filed on is a) app	proved or b) disapproved by t	he Examiner.			
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)					
10. Other:	SUP	CAMPS FOR SOME CHRISTOPHER S. F. LOW ERVISORY PATENT EXAMINER ECHNOLOGY CENTER 1800			

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Continuation of 2. NOTE: The compositions comprising thymol/carvacrol for parenteral administration read on the compositions of Ropapharm B.V. wherein the thymol/carvacrol compositions are in the form of an injectable solution (page 2, paragraph 0008).